Apr 8 |
Pluri stock jumps 9% on US patent for immune cell production
|
Apr 8 |
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
|
Mar 27 |
Pluri to implement a 1-for-8 reverse stock split
|
Mar 27 |
Pluri Inc. Announces 1-for-8 Reverse Share Split
|
Mar 21 |
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
|
Mar 14 |
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
|
Mar 11 |
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
|
Mar 6 |
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
|
Feb 28 |
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
|
Feb 14 |
Pluri Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)
|